Antifibrotic potential of bone marrow‑derived mesenchymal stem cells in biliary atresia mice

Lei, Jun; Chai, Yong; Xiao, Jianghong; Hu, Huakun; Liu, Zhiqiang; Xiao, Yao; Yi, Lijun; Huang, Jinshi; Xiang, Tianxin; Zhang, Shouhua

doi:10.3892/mmr.2018.9353

Cited by 8 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lei et al investigated the anti-fibrotic potential of bone marrow-derived MSCs on liver fibrosis induced by BA [ 90 ]. An inflammatory cholangiopathy is induced in the murine model of BA using RRV infection in the newborn BALB/c mice.…”

Section: Mesenchymal Stromal Cells (Msc) Transplantationmentioning

confidence: 99%

“…The pathological phenotype is similar to that in human BA. They demonstrated that BM-MSCs treatment significantly restored liver enzymatic function and bilirubin metabolism and inhibited oxidative stress and alleviated liver fibrosis of the RRV-induced murine model of BA [ 90 ]. Collagen IV and COL1A1 were also highly expressed in the liver tissue of the murine model group but BM-MSC treatment significantly reduced their expression.…”

Section: Mesenchymal Stromal Cells (Msc) Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Cellular Therapies in Pediatric Liver Diseases

Vimalesvaran

Nulty

Dhawan

2022

Cells

View full text Add to dashboard Cite

Liver transplantation is the gold standard for the treatment of pediatric end-stage liver disease and liver based metabolic disorders. Although liver transplant is successful, its wider application is limited by shortage of donor organs, surgical complications, need for life long immunosuppressive medication and its associated complications. Cellular therapies such as hepatocytes and mesenchymal stromal cells (MSCs) are currently emerging as an attractive alternative to liver transplantation. The aim of this review is to present the existing world experience in hepatocyte and MSC transplantation and the potential for future effective applications of these modalities of treatment.

show abstract

Section: Mesenchymal Stromal Cells (Msc) Transplantationmentioning

confidence: 99%

Section: Mesenchymal Stromal Cells (Msc) Transplantationmentioning

confidence: 99%

Cellular Therapies in Pediatric Liver Diseases

Vimalesvaran

Nulty

Dhawan

2022

Cells

View full text Add to dashboard Cite

show abstract

“…Additionally, if autologous stem cells are used then there would not be a requirement for immunosuppression (unlike hepatocyte transplantation). In a mouse model of biliary atresia, animals were given bone marrow-derived mesenchymal stem cells via intraperitoneal injection and the authors reported significantly improved AST, ALT, total and direct bilirubin along with improved histologic features and markers of hepatic fibrosis 14 days later (162). There is a case report of human hepatic progenitor cells being infused through the hepatic artery for a 1 year old patient with reported biliary atresia which reported improvement in several lab values including bilirubin at 2 months post-infusion (163).…”

Section: Hepatocyte Transplant Stem Cell Infusions and Gene Therapiesmentioning

confidence: 99%

Pediatric Cholestatic Liver Disease: Review of Bile Acid Metabolism and Discussion of Current and Emerging Therapies

Kriegermeier

Green

2020

Front. Med.

View full text Add to dashboard Cite

Cholestatic liver diseases are a significant cause of morbidity and mortality and the leading indication for pediatric liver transplant. These include diseases such as biliary atresia, Alagille syndrome, progressive intrahepatic cholestasis entities, ductal plate abnormalities including Caroli syndrome and congenital hepatic fibrosis, primary sclerosing cholangitis, bile acid synthesis defects, and certain metabolic disease. Medical management of these patients typically includes supportive care for complications of chronic cholestasis including malnutrition, pruritus, and portal hypertension. However, there are limited effective interventions to prevent progressive liver damage in these diseases, leaving clinicians to ultimately rely on liver transplantation in many cases. Agents such as ursodeoxycholic acid, bile acid sequestrants, and rifampicin have been mainstays of treatment for years with the understanding that they may decrease or alter the composition of the bile acid pool, though clinical response to these medications is frequently insufficient and their effects on disease progression remain limited. Recently, animal and human studies have identified potential new therapeutic targets which may disrupt the enterohepatic circulation of bile acids, alter the expression of bile acid transporters or decrease the production of bile acids. In this article, we will review bile formation, bile acid signaling, and the relevance for current and newer therapies for pediatric cholestasis. We will also highlight further areas of potential targets for medical intervention for pediatric cholestatic liver diseases.

show abstract

“…This technique can be performed in various strains of mice. Recent studies using this model have demonstrated the functional roles of the gut microbiome and bone marrow-derived mesenchymal stem cells in BA [85,86]. The viral injection model is the sole wellestablished BA model currently available, and studies using this model are limited.…”

Section: Ba Modelsmentioning

confidence: 99%

Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets

Sato

Glaser

Kennedy

et al. 2019

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

Introduction-The common predominant clinical features of cholangiopathies such as primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), and biliary atresia (BA) are biliary damage/senescence and liver fibrosis. Curative therapies are lacking, and liver transplantation is only option. An understanding of the mechanisms and pathogenesis is needed to develop novel therapies. Previous studies have developed various disease-based research models and have identified candidate therapeutic targets. Areas covered-This review summarizes recent studies performed in preclinical models of cholangiopathies and the current understanding of the pathophysiology representing potential targets for novel therapies. A literature search was conducted in PubMed using the combination of the searched term "cholangiopathies" with one or two keywords including "model", "cholangiocyte", "animal", or "fibrosis". Papers published within five years were obtained. Expert opinion-Access to appropriate research models is a key challenge in cholangiopathy research; establishing more appropriate models for PBC is an important goal. Several preclinical studies have demonstrated promising results and have led to novel therapeutic approaches, especially for PSC. Further studies on the pathophysiology of PBC and BA are necessary to identify candidate targets. Innovative therapeutic approaches such as stem cell transplantation have been introduced, and those therapies could be applied to PSC, PBC, and BA.

show abstract

Antifibrotic potential of bone marrow‑derived mesenchymal stem cells in biliary atresia mice

Cited by 8 publications

References 26 publications

Cellular Therapies in Pediatric Liver Diseases

Cellular Therapies in Pediatric Liver Diseases

Pediatric Cholestatic Liver Disease: Review of Bile Acid Metabolism and Discussion of Current and Emerging Therapies

Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets

Contact Info

Product

Resources

About